UnitedHealth Group Inc. (NYSE:UNH) reportedly announced on Tuesday that it will remove AbbVie Inc.’s (NYSE:ABBV) blockbuster drug Humira from some of its preferred reimbursement lists starting January ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
AbbVie did not immediately respond to a request for comment, but has previously said it expects to retain a lower share of the Humira market next year. Pharmacy benefit managers, which act as ...
Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback